FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study

Related Information
Company: AstraZeneca

FDA rejected ivonescimab in its present form, issuing a Complete Response Letter (CRL) for the Biologics License Application (BLA), Summit Therapeutics Inc. (NASDAQ: SMMT) announced on November 15, 2026, in a press release on its investor relations site. The BLA covers ivonescimab combined with platinum-containing chemotherapy. The indication is locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody.

For readers asking why the FDA rejected ivonescimab, Summit’s release points to a single evidentiary issue. The CRL indicates that the BLA cannot be approved in its present form. According to Summit, the FDA determined that substantial evidence of effectiveness is not established without a statistically significant overall survival (OS) improvement. The agency also indicated that a progression-free survival (PFS) benefit without a significant OS benefit does not support a positive benefit-risk profile.

Summit said it is disappointed for patients and families awaiting additional treatment options. Robert W. Duggan, Chairman and Co-Chief Executive Officer, said the global HARMONi study provided the basis for an option these patients needed. He added that nothing changes in the company’s belief in ivonescimab, citing five positive Phase III studies between Summit and Akeso. Dr. Maky Zanganeh, President and Co-Chief Executive Officer, spoke of the importance of multiple treatment options. Summit said it will continue its clinical development program.

Why the FDA Rejected Ivonescimab Without a Significant Overall Survival Benefit

In Summit’s account, the FDA rejected ivonescimab because the primary OS analysis did not reach statistical significance. The release states that no FDA-approved regimens have demonstrated a statistically significant OS benefit in this patient setting. In that primary analysis, ivonescimab plus chemotherapy showed a positive trend. The gap between a met PFS endpoint and an unmet OS threshold is the core of the regulatory outcome.

In a post-hoc analysis, Summit reported longer-term follow-up of western patients. It said this showed a consistent OS benefit across regions, with a hazard ratio of 0.76 in the full population, the Asian patients and the western patients. The release does not state whether the FDA considered this analysis in its determination. Summit also said the primary PFS analysis was supported by longer-term follow-up showing a consistent magnitude of benefit, with more mature data from western patients.

Advertisement

The release does not disclose the full text of the CRL, a resubmission timeline, or any additional FDA requests such as further trials. Those details are Not disclosed in the source. Any statement about next regulatory steps would therefore be speculation, and this article does not offer one. Readers should consult Summit’s filings and future announcements for updates.

HARMONi Trial Data Behind the Summit Therapeutics BLA After FDA Rejected Ivonescimab

The BLA was supported by HARMONi, a global, randomized, double-blind Phase III trial registered as NCT06396065. It compared ivonescimab plus platinum-containing chemotherapy against placebo plus the same chemotherapy. Participants had EGFR-mutated, locally advanced or metastatic non-squamous NSCLC and had previously been treated with a third-generation EGFR TKI.

HARMONi has two primary endpoints, PFS and OS. According to Summit, it met the PFS primary endpoint. The company says this made it the first global Phase III study of an immunotherapy-based regimen to show a statistically significant PFS improvement in this setting. The FDA rejected ivonescimab even though HARMONi met its PFS endpoint, because the agency indicated that PFS without a significant OS result did not support approval.

On safety, Summit says ivonescimab plus chemotherapy showed an acceptable and manageable profile consistent with earlier studies. It reports no new safety signals and comparable rates of discontinuation and death between arms. Sixteen patients (7.3%) discontinued ivonescimab because of treatment-related adverse events (TRAEs), versus 11 patients (5.0%) who discontinued placebo. Four patients (1.8%) in the ivonescimab arm and five (2.3%) in the chemotherapy-alone arm died from TRAEs.

Summit Therapeutics Pipeline Plans After FDA Rejected Ivonescimab in NSCLC

Summit is developing ivonescimab in NSCLC, colorectal cancer (CRC), urothelial carcinoma (UC) and renal cell carcinoma (RCC). The company’s stated position is that nothing changes after the FDA rejected ivonescimab in this NSCLC setting. It cites five positive Phase III studies between Summit and Akeso. The ivonescimab profile includes multiregional Phase II or Phase III trials in several proposed indications and settings beyond HARMONi.

Advertisement

HARMONi-3 (Phase III) combines ivonescimab with chemotherapy in first-line metastatic NSCLC, with squamous and non-squamous cohorts analyzed separately. HARMONi-7 (Phase III) tests ivonescimab monotherapy in first-line metastatic NSCLC with high PD-L1 expression. HARMONi-GI3 (Phase III) pairs ivonescimab with chemotherapy in first-line unresectable metastatic CRC. HARMONi-GU1 (Phase II/III) adds enfortumab vedotin in first-line metastatic UC, and SMT112-216 (Phase II) studies combination regimens in first-line metastatic clear cell RCC.

Summit also lists collaborations to test ivonescimab with other compounds. These include AstraZeneca and Daiichi Sankyo (DATROWAY, datopotamab deruxtecan), AstraZeneca (sonesitatug vedotin) and Revolution Medicines (RAS(ON) inhibitors including RASONQUE, daraxonrasib). They also include GSK (risvutatug rezetecan) and Arcus Biosciences (casdatifan). The release does not state that any partnership changed after the FDA rejected ivonescimab. Several plans are described as planned or intended, so they remain forward-looking.

Ivonescimab Mechanism, Akeso Origins and Regulatory Status After FDA Rejected Ivonescimab

Two cooperative-group studies also feature ivonescimab. GORTEC 2024-04 ILLUMINE (NCT07264075) is a Phase III in first-line advanced head and neck squamous cell carcinoma (HNSCC). It compares ivonescimab alone, and with Akeso’s anti-CD47 antibody ligufalimab, against pembrolizumab. EA2251, run with ECOG-ACRIN, is a registration-enabling Phase II/III in first-line advanced biliary tract cancer. It compares ivonescimab plus chemotherapy with pembrolizumab or durvalumab plus chemotherapy.

Ivonescimab is known as SMT112 in Summit’s license territories and AK112 elsewhere. It combines PD-1 blockade with anti-VEGF effects in one tetravalent bispecific antibody. Summit says it shows cooperative binding, with higher PD-1 affinity in the presence of VEGF. It also cites a half-life of 6 to 7 days after the first dose, rising to about 10 days at steady state. That design is Summit’s stated rationale for differentiation, yet the FDA rejected ivonescimab in this application on the basis of OS. Akeso Inc. (HKEX: 9926.HK) invented the molecule.

Advertisement

Ivonescimab is investigational and not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. It first received marketing authorization in China in May 2024, and no PD-1 x VEGF bispecific antibodies are currently approved in the U.S. Citing Akeso, Summit says over 5,000 patients have been treated in clinical studies globally and over 100,000 in a commercial setting in China. Even after the FDA rejected ivonescimab in this indication, the molecule’s exposure data remain substantial.

This report on how the FDA rejected ivonescimab draws exclusively on Summit’s November 15, 2026 release. Statements about future trials, partnerships and regulatory discussions are forward-looking. The company notes that outcomes of discussions with regulators, including the FDA, could cause actual results to differ materially.

Related Leads